LIXT News and Press, Lixte Biotechnology Holdings Inc. From 01/21/26

2026-01-21 09:46:26 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul and scheduled for Feb. 19 at Morehouse College in Atl...

Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & Soul Summit  will take place F...

2026-01-20 12:21:21 ET Lixte Biotechnology Holdings (NASDAQ: LIXT) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, in Atlantic City, N.J. The company said Chief Executive Officer Geordan Pursglove&...

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the...

2026-01-13 09:45:00 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) , a clinical-stage pharmaceutical company focused on advancing differentiated cancer therapies, announced that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate co...

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- via  IBN – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) , a biotech company focused on advancing cancer treatments, has engaged IBN , a multifaceted financial news and publishing company serving private and public entities,...

2026-01-08 09:05:00 ET Lixte Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combin...

2026-01-07 09:05:00 ET LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical ne...

2026-01-07 09:03:56 ET Lixte Biotechnology Holdings (NASDAQ: LIXT) entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of Common Stock and pre-funded and investor warrants at a pri...

--Plans to double the Number of Patients in Study--  --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a biotech ...